DOP2012000250A - COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO - Google Patents

COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO

Info

Publication number
DOP2012000250A
DOP2012000250A DO2012000250A DO2012000250A DOP2012000250A DO P2012000250 A DOP2012000250 A DO P2012000250A DO 2012000250 A DO2012000250 A DO 2012000250A DO 2012000250 A DO2012000250 A DO 2012000250A DO P2012000250 A DOP2012000250 A DO P2012000250A
Authority
DO
Dominican Republic
Prior art keywords
iron deficiency
profilaxis
iii
treatment
compounds
Prior art date
Application number
DO2012000250A
Other languages
English (en)
Inventor
Franz Durrenberger
Wilm Buhr
Felix Funk
Thomas Bark
Susanna Burckhardt
Michael Burgert
Camillo Canclini
Peter Geisser
Aris Kalogerakis
Simona Mayer
Erik Philipp
Stefan Reim
Diana Sieber
Jorg Schmitt
Katrin Schwarz
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42710524&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000250(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of DOP2012000250A publication Critical patent/DOP2012000250A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA INVENCIÓN SE RELACIONA CON COMPUESTOS DEL COMPLEJO DE HIERRO(III) ASÍ COMO CON LAS COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA SU USO COMO MEDICAMENTOS, EN PARTICULAR PARA EL TRATAMIENTO Y/O PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO.
DO2012000250A 2010-03-23 2012-09-20 COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO DOP2012000250A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10157387 2010-03-23

Publications (1)

Publication Number Publication Date
DOP2012000250A true DOP2012000250A (es) 2013-02-15

Family

ID=42710524

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000250A DOP2012000250A (es) 2010-03-23 2012-09-20 COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO

Country Status (25)

Country Link
US (2) US9394324B2 (es)
EP (1) EP2549991B1 (es)
JP (1) JP5648120B2 (es)
KR (1) KR101529273B1 (es)
CN (1) CN102892415B (es)
AR (1) AR080802A1 (es)
AU (1) AU2011231710B2 (es)
BR (1) BR112012023780A2 (es)
CA (1) CA2793153C (es)
CL (1) CL2012002624A1 (es)
CO (1) CO6630090A2 (es)
CR (1) CR20120478A (es)
DO (1) DOP2012000250A (es)
ES (1) ES2660202T3 (es)
MA (1) MA34067B1 (es)
MX (1) MX2012010950A (es)
NZ (1) NZ602289A (es)
PE (1) PE20130246A1 (es)
PH (1) PH12012501814A1 (es)
RU (1) RU2589710C2 (es)
SG (1) SG183972A1 (es)
TN (1) TN2012000457A1 (es)
TW (1) TWI426900B (es)
WO (1) WO2011117225A1 (es)
ZA (1) ZA201207550B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140248342A1 (en) * 2011-05-31 2014-09-04 Vifor (International) Ag Fe(III) 2,4-Dioxo-1-Carbonyl Complexes For Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anaemias
WO2013054770A1 (ja) * 2011-10-12 2013-04-18 Ｓｂｉファーマ株式会社 がん性貧血改善・予防剤
EP2604615A1 (de) * 2011-12-12 2013-06-19 Sika Technology AG Bismuthaltiger Katalysator für Polyurethan-Zusammensetzungen
EP2604618A1 (de) 2011-12-12 2013-06-19 Sika Technology AG Metall-Komplexverbindungen als Katalysatoren für Polyurethan-Zusammensetzungen
EP2604617A1 (de) 2011-12-12 2013-06-19 Sika Technology AG Eisen(III)-Komplexverbindungen als Katalysatoren für Polyurethan-Zusammensetzungen
BR112015014917A2 (pt) * 2012-12-21 2017-07-11 Vifor Int Ag uso de compostos de complexo de ferro(iii)-2-oxo-butanodiamida ou sais farmaceuticamente aceitáveis dos mesmos; medicamento; e uso de composições
CN105228621A (zh) * 2013-03-28 2016-01-06 维福（国际）股份有限公司 用于缺铁症状和缺铁性贫血的治疗和预防的Fe(III)络合化合物
CN103819425A (zh) * 2014-03-05 2014-05-28 南通惠康国际企业有限公司 一种树脂固化剂n-乙酰乙酰基吗啉的制备方法
WO2015198304A1 (en) 2014-06-22 2015-12-30 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
KR102920596B1 (ko) 2018-05-16 2026-01-30 세바 상뜨 아니말르 수의학적 조성물 및 이의 비-인간 포유동물에서 철 결핍을 조절하기 위한 용도
JP7421638B2 (ja) * 2019-08-30 2024-01-24 ダウ グローバル テクノロジーズ エルエルシー ポリエーテルポリオールおよびポリウレタン発泡体のアルデヒド排出量を減少させるための方法
WO2021222898A1 (en) * 2020-05-01 2021-11-04 North Carolina State University Nutritional supplements comprising dietary metal complexes in a matrix of cellulosic materials
RU2763135C1 (ru) * 2021-04-23 2021-12-27 Виктор Павлович Ремез Фармакологическая композиция для лечения железодефицитной анемии
WO2023041778A2 (en) * 2021-09-20 2023-03-23 Novaled Gmbh Compound, semiconductor layer comprising compound and organic electronic device
KR102623739B1 (ko) * 2022-07-28 2024-01-11 주식회사 페라메드 시트르산과 철을 포함하는 착화합물 및 그를 포함하는 식품 조성물
CN116199572B (zh) * 2023-03-02 2025-01-14 南京师范大学 一种铁催化酮α位溴化的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474670A (en) 1892-05-10 Automatic fire-alarm
US2832790A (en) * 1954-09-28 1958-04-29 Du Pont 4-negative functionally substituted 2, 3, 5-trichalcogenpyrrolidines, their salts, and methods for preparing them
GB842637A (en) 1955-12-27 1960-07-27 Andre Georges Jules Jallais Glass frames, more especially for forced cultivation
EP0107458B1 (en) 1982-10-22 1987-07-29 National Research Development Corporation Pharmaceutical compositions
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
US4788281A (en) 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
GB8410289D0 (en) 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
IT1222654B (it) 1987-09-14 1990-09-12 Schering Ag Complesso micellare di ferro-citrato
JPH0283400A (ja) 1988-09-21 1990-03-23 Snow Brand Milk Prod Co Ltd 鉄カゼインの製造方法
ES2044777B1 (es) 1992-03-03 1994-08-01 Dabeer Sa Procedimiento de obtencion de un quelato de hierro de gran solubilidad.
US20030236224A1 (en) 1997-12-09 2003-12-25 Hedlund Bo E. Modified polysaccharides exhibiting altered biological recognition
IT1297022B1 (it) 1997-12-24 1999-08-03 Chemi Spa Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
MX2007004036A (es) 2004-10-08 2007-05-24 Unilever Nv Complejo de hierro para uso en el tratamiento y/o prevencion de trastornos nutricionales.
US20090035385A1 (en) 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
CN100443485C (zh) 2005-04-08 2008-12-17 吴华君 叶绿酸合铁钠盐衍生物、制备方法及用途
WO2007062546A1 (fr) 2005-11-30 2007-06-07 Chongqing Pharmaceutical Research Institute Co., Ltd. Complexes fer-saccharide faciles a reconstituer et leur procede de fabrication
EP1997833A1 (de) 2007-05-29 2008-12-03 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
CN101481404B (zh) 2008-12-17 2011-10-05 中国农业大学 一种酶解乳蛋白亚铁络合物微胶囊补铁剂及其制备方法

Also Published As

Publication number Publication date
MX2012010950A (es) 2012-11-12
AR080802A1 (es) 2012-05-09
KR20130031250A (ko) 2013-03-28
AU2011231710A1 (en) 2012-09-27
US20130109662A1 (en) 2013-05-02
AU2011231710B2 (en) 2013-07-25
RU2589710C2 (ru) 2016-07-10
US9943498B2 (en) 2018-04-17
TWI426900B (zh) 2014-02-21
CO6630090A2 (es) 2013-03-01
TN2012000457A1 (en) 2014-01-30
CN102892415A (zh) 2013-01-23
CL2012002624A1 (es) 2013-02-01
KR101529273B1 (ko) 2015-06-16
CN102892415B (zh) 2016-10-19
PE20130246A1 (es) 2013-04-07
CA2793153A1 (en) 2011-09-29
NZ602289A (en) 2014-01-31
SG183972A1 (en) 2012-10-30
ES2660202T3 (es) 2018-03-21
US9394324B2 (en) 2016-07-19
RU2012144844A (ru) 2014-04-27
EP2549991A1 (de) 2013-01-30
JP5648120B2 (ja) 2015-01-07
PH12012501814A1 (en) 2012-12-10
JP2013522343A (ja) 2013-06-13
WO2011117225A1 (de) 2011-09-29
CR20120478A (es) 2013-03-11
CA2793153C (en) 2016-03-29
MA34067B1 (fr) 2013-03-05
US20160310459A1 (en) 2016-10-27
TW201136583A (en) 2011-11-01
ZA201207550B (en) 2013-06-26
BR112012023780A2 (pt) 2018-07-24
EP2549991B1 (de) 2017-11-22

Similar Documents

Publication Publication Date Title
CR20120478A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
CL2017002650A1 (es) Compuestos novedosos
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
TR201816379T4 (tr) DNA-PK inhibitörleri.
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CR20150326A (es) Inhibidores de autotaxina
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
EA201590005A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
ECSP11011558A (es) Nuevos compuestos químicos.
MX2015001553A (es) Composiciones y metodos para reducir el contenido de alcohol en sangre.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico